CN101969960A - 使用γ抑制剂化合物减轻疼痛的方法 - Google Patents

使用γ抑制剂化合物减轻疼痛的方法 Download PDF

Info

Publication number
CN101969960A
CN101969960A CN2008800188672A CN200880018867A CN101969960A CN 101969960 A CN101969960 A CN 101969960A CN 2008800188672 A CN2008800188672 A CN 2008800188672A CN 200880018867 A CN200880018867 A CN 200880018867A CN 101969960 A CN101969960 A CN 101969960A
Authority
CN
China
Prior art keywords
peptide
composition
inhibitory
modified
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008800188672A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·D·哈里森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kai Pharmaceuticals Inc
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of CN101969960A publication Critical patent/CN101969960A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2008800188672A 2007-04-06 2008-04-07 使用γ抑制剂化合物减轻疼痛的方法 Pending CN101969960A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91058807P 2007-04-06 2007-04-06
US60/910,588 2007-04-06
PCT/US2008/059591 WO2008124698A2 (en) 2007-04-06 2008-04-07 Methods of use of gamma inhibitor compounds for the attenuation of pain

Publications (1)

Publication Number Publication Date
CN101969960A true CN101969960A (zh) 2011-02-09

Family

ID=39831558

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800188672A Pending CN101969960A (zh) 2007-04-06 2008-04-07 使用γ抑制剂化合物减轻疼痛的方法

Country Status (8)

Country Link
US (1) US20090062178A1 (cg-RX-API-DMAC10.html)
EP (1) EP2144615A4 (cg-RX-API-DMAC10.html)
JP (1) JP2010523598A (cg-RX-API-DMAC10.html)
CN (1) CN101969960A (cg-RX-API-DMAC10.html)
AU (1) AU2008237138B2 (cg-RX-API-DMAC10.html)
CA (1) CA2693256A1 (cg-RX-API-DMAC10.html)
MX (1) MX2009010757A (cg-RX-API-DMAC10.html)
WO (1) WO2008124698A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017583B2 (en) 2007-01-19 2011-09-13 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain
JP5801197B2 (ja) * 2008-09-03 2015-10-28 ノノ インコーポレイテッド 痛みの治療に関する薬剤及び方法
US11208446B2 (en) 2016-11-01 2021-12-28 Memorial Sloan Kettering Cancer Cenier Agents and methods for treating CBP-dependent cancers
IT201800009384A1 (it) * 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
TWI238191B (en) * 2000-02-08 2005-08-21 Amgen Inc IL-17 like molecules and uses thereof
JP2005523326A (ja) * 2002-04-22 2005-08-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ プロテインキナーゼｃのペプチドインヒビター
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US8017583B2 (en) * 2007-01-19 2011-09-13 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain

Also Published As

Publication number Publication date
US20090062178A1 (en) 2009-03-05
JP2010523598A (ja) 2010-07-15
AU2008237138B2 (en) 2013-11-21
MX2009010757A (es) 2010-02-24
CA2693256A1 (en) 2008-10-16
AU2008237138A1 (en) 2008-10-16
EP2144615A2 (en) 2010-01-20
WO2008124698A3 (en) 2008-12-24
EP2144615A4 (en) 2011-02-16
WO2008124698A2 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
KR101873773B1 (ko) 류마티즘 관절염 예방 또는 치료 조성물
CN105899224B (zh) 用于治疗和预防良性前列腺增生的组合物
KR100944318B1 (ko) 항암 및 상처 치유용 화합물
ES2624180T3 (es) Modulación de la actividad de proneurotrofinas
ES3041075T3 (en) Peptides and compositions thereof for use in the prevention and treatment of macular degeneration
CN117752766A (zh) 治疗线粒体疾病的方法
BRPI0708737A2 (pt) mÉtodo de prevenÇço ou reduÇço do risco ou incidÊncia de cÂncer utilizando-se peptÍdeos baseados na proteÍna na cadeia neural
WO2016130143A2 (en) Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
US20040214777A1 (en) Peptide activators of VEGF
CN104837485A (zh) 血管紧张素在治疗脑部病况中的用途
CN110381984B (zh) 用于改善性功能的组合物和方法
JP2007527856A (ja) 癌細胞を選択的に死滅させるＲａｓＧＡＰ由来ペプチド
CN102448981B (zh) 甲基乙二醛清除化合物及其用于预防和治疗疼痛和/或痛觉过敏的用途
AU2008237138B2 (en) Methods of use of gamma inhibitor compounds for the attenuation of pain
CN105848720A (zh) 用于诱导葡萄糖摄取的方法
CN111712252A (zh) 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂
Yeargans et al. Carnosine promotes the heat denaturation of glycated protein
CN101678063B (zh) 使用ε抑制剂化合物减轻疼痛的方法
US20060281670A1 (en) Compositions and methods for modulating angiogenesis
KR20190139910A (ko) 브라시카세아에 단백질 추출물 및 그의 용도
US9815867B2 (en) Peptide for inhibiting vascular endothelial growth factor receptor
CN101180311A (zh) 抑制转谷氨酰胺酶的肽
WO2020083916A1 (en) Virally expressed inhibitors of pdz domains, such as pick1 and uses thereof
WO2000066721A2 (en) Decreasing adipose mass by altering rsk2 activity
EP3820498A1 (en) Peptide for disease treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110209